• Continued growth in sales of NervAlign® Nerve Cuff
• Positive clinical study data demonstrating improved patient outcomes
• Expansion through several non-US partnerships

ReNerve Limited, an Australian biotechnology company developing innovative products for peripheral nerve injury repair, presented its Q3 FY25 Quarterly Report. The quarter saw continued growth in sales of the NervAlign® Nerve Cuff, with revenue reaching A$75,000, a 39% increase over the previous quarter. The company also presented positive clinical study data demonstrating statistically significant improvements in patient outcomes when using the NervAlign® Nerve Cuff in peripheral nerve repair surgery. Patients using the Nerve Cuff experienced greater reduction in post-operative pain scores and higher satisfaction, with 93% indicating they would undergo the surgery again compared to 70% in the control group. During the period, ReNerve also expanded through several non-US partnerships, including exclusive distribution in Mexico, commercial marketing approval in Thailand, first hospital sales in Hong Kong, and a strategic partnership in India. The company remains well-funded, with A$5.8 million in cash reserves at the end of the quarter.

ReNerve reported Q3 FY25 sales of A$75,000, a 39% increase over the previous quarter, contributing to cumulative FY25 nine-month sales of A$177,000.